Publication details
Neuroleptický maligní syndrom a jeho řešení v klinické praxi z perspektivy současných doporučených postupů
| Title in English | Neuroleptic malignant syndrome and its management in clinical practice from the perspective of current guidelines |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská psychiatrie |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.cspsychiatr.eu/detail.php?stat=1375 |
| Keywords | neuroleptic malignant syndrome; prevalence; guidelines; benzodiazepines; bromocriptine; dantrolene; electroconvulsive therapy |
| Description | The paper deals with recent aspects of diagnosis and treatment of neuroleptic malignant syndrome (NMS). NMS is an antipsychotic-induced, life-threatening condition, characterized by hyperpyrexia, muscle rigidity, qualitative alteration of consciousness and autonomic nervous system dys-regulation. NMS prevalence and mortality rates have declined over the past 30 years, most likely due to early recognition of the syndrome and appropriate intervention. Recent reports suggest a prevalence of 0.02-0.03%, and 5.6% mortality. Treatment includes withdrawal of the offending dopamine antagonist, supportive care and may include the use of specific pharmacotherapies (benzodiazepines, bromocriptine, amentadine, dantrolene) and electroconvulsive therapy. Nonetheless, clinicians, especially primary care clinicians who are using antipsychotics more often for adjunctive treatments, must be cognizant of this syndrome. |